2nd Quarter - Amendment

DELAHUNT GROUP, LLC for HEALIANCE PHARMACEUTICALS

Firm
Client
Income
$50,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 11, 2014 $50,000 Replaced
2nd Quarter - Amendment (this page) Jan 9, 2015 $50,000 Yes

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Foreign Relations FOR

Issues related to issuance of supplemental OFAC license.

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

LobbyistCovered position, as disclosed
WILLIAM DELAHUNT —
JOHN H. SUNUNU —

Contacted: HOUSE OF REPRESENTATIVES; State, Dept of (DOS); Natl Security Agency (NSA); SENATE

Pharmacy PHA

Issues related to issuance of supplemental OFAC license

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

LobbyistCovered position, as disclosed
WILLIAM DELAHUNT —
JOHN H. SUNUNU —

Contacted: HOUSE OF REPRESENTATIVES; Natl Security Agency (NSA); SENATE; State, Dept of (DOS)

Health Issues HCR

Issues related to issuance of supplemental OFAC license

Foreign entity interest: Foreign entity Digen Pharmaceuticals will benefit from work for client.

LobbyistCovered position, as disclosed
WILLIAM DELAHUNT —
JOHN H. SUNUNU —

Contacted: SENATE; Natl Security Agency (NSA); HOUSE OF REPRESENTATIVES; State, Dept of (DOS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.